The immunosuppression caused by the CTLA-4 pathway may limit the effectiveness of cellular therapy based on the tumor antigen-presenting dendritic cells and cytokine-induced killer cells (DC-CIK). The gene discussed is CTLA4; the disease is neoplasm.